Physician profile
Kyle Gleeson
NPI 1831772441
$1,805.72
in general payments reported to CMS, 2019-2025
12 companies · $180 in 2025
The $180 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $532 · 2022: $618 · 2023: $294 · 2024: $181 · 2025: $180.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $656.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $655.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aroa Biosurgery Incorporated | $354.06 | 2022-2023 | |
| Smith+Nephew, INC. | $272.98 | 2021-2025 | Collagenase Santyl, Grafix Pl, Stravix Pl |
| Horizon Therapeutics Plc | $249.90 | 2021-2022 | |
| Integra Lifesciences Corporation | $211.70 | 2021 | |
| Paratek Pharmaceuticals, INC. | $160.63 | 2022-2025 | Nuzyra |
| Kerecis Limited | $129.41 | 2024-2025 | Kerecis Surgiclose, Kerecis Graftguide, Kerecis Omega3 Marigen |
| Organogenesis INC. | $123.84 | 2023 | Puraply Antimicrobial |
| Abbvie INC. | $118.58 | 2021 | |
| Terumo Medical Corporation | $117.88 | 2024 | Navicross |
| Kci USA, INC. | $28.69 | 2021 | |
| Reprise Biomedical, INC. | $19.62 | 2024 | Miro3d |
| Convatec INC. | $18.43 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Gleeson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.